Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Cancer-drug setback...

    Cancer-drug setback sends Merck shares down again

    Written by supriya kashyap kashyap Published On 2017-11-02T11:37:04+05:30  |  Updated On 2 Nov 2017 11:37 AM IST
    Cancer-drug setback sends Merck shares down again

    New York: A setback for Merck & Co’s (MRK.N) key cancer drug sent the drugmaker’s stock swooning for a second straight session, putting the shares on track for their biggest two-day decline in more than eight years.


    Late on Friday, Merck withdrew an application for European use of its flagship drug Keytruda as an initial, or first-line, treatment for advanced lung cancer in combination with chemotherapy, raising questions about future sales.



    The Keytruda/chemo combination is already approved in the United States based on initial promising data. But the company determined that a similar European first-line approval without more mature late-stage data was unlikely.

    Lung cancer is by far the most lucrative oncology market with first-line approval providing access to the most patients.


    In the wake of the news, at least three analysts cut their ratings on Merck's stock, a component of the blue-chip Dow Jones Industrial Average. DJI, while other analysts lowered their target prices for the stock.


    “We are downgrading MRK shares to Equal Weight from Overweight based on diminished upside potential from Keytruda, which is by far Merck’s biggest value driver,” Barclays analyst Geoff Meacham said in his downgrade note.


    Aside from the European withdrawal, Meacham and other analysts also cited delays for another Keytruda study, revealed on Friday morning. Merck said a decision to make overall survival a main goal for a large, pivotal lung cancer trial of Keytruda plus chemotherapy would delay those results until February 2019.


    Merck shares fell 5.6 percent to $54.95 on Monday, touching their lowest point since May 2016. The stock had dropped 6 percent on Friday following the company’s third-quarter results.


    The drugmaker said that the cost of a June cyberattack that temporarily crippled manufacturing coupled with lower sales of off-patent products caused its third-quarter revenue to fall 2 percent to $10.33 billion, even as Keytruda sales topped $1 billion for the first time.


    The combined, roughly 11-percent two-day decline for Merck shares would be the biggest since February 2009.



    Merck’s setback boosted shares of Bristol-Myers Squibb Co (BMY.N), which sells a rival cancer therapy. Bristol-Myers shares were up 1.6 percent.

    Pharmaceutical stocks have endured a rocky month so far as earnings results have poured in. The NYSE Arca Pharmaceutical index. DRG is down 2 percent in October against a 2.1 percent rise for the overall S&P 500. SPX.


    Pharmaceutical heavyweight Pfizer Inc (PFE.N) is set to report results on Tuesday.


    additional reporting by Bill Berkrot; Editing by Nick Zieminski
    Bristol-Myers Squibbcancercancer drugchemotherapyGeoff MeachamKeytrudalung cancerMerckPfizer
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok